Drug Trial Radar · NCT04540211
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
461
Actual
Start
Oct 30, 2020
Primary completion
Feb 13, 2023
Study completion Aug 28, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC). Participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase: Arm A: Atezolizumab plus Tiragolumab and PC Arm B: Atezolizumab placebo plus Tiragolumab placebo and PC Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab matching placebo plus tiragolumab matching placebo (Arm B).
Conditions
- Esophageal Cancer
Interventions
AtezolizumabDrug
Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
TiragolumabDrug
Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
PaclitaxelDrug
Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
CisplatinDrug
Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
Atezolizumab Matching PlaceboDrug
Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Tiragolumab Matching PlaceboDrug
Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Independent Review Facility (IRF)-Assessed Progression-free Survival (PFS)Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 19 months)
- Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 27.5 months)
Locations
67 sites in 5 countries. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Anhui, China
Anyang Tumor Hosptial
Anyang, China
Beijing Luhe Hospital Capital Medical University
Beijing, China
the First Hospital of Jilin University
Changchun, China
Jilin Cancer Hospital
Changchun, China
Hunan Cancer Hospital
Changsha, China
Affiliated Hospital of Chengde Medical University
Chengde, China
Sichuan Provincial Cancer Hospital
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing Sanxia Central Hospital
Chongqing, China
The First People's Hospital of Foshan
Foshan, China
Fujian Cancer Hospital
Fuzhou, China
Fujian Provincial Hospital
Fuzhou, China
Southern Medical University Nanfang Hospital
Guangdong Province Guangzhou City, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Anhui Province Cancer Hospital
Hefei, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Huai'an First People's Hospital
Huai'an, China
The Second People's Hospital of Huai'an
Huai'an, China
Affiliated Hopsital of Jining Medical University
Jining, China
Gansu Province People Hospital
Lanzhou, China
The First People's Hospital of Lian Yun Gang
Lianyungang, China
Linyishi Cancer Hospital
Linyi, China
The First Affiliated Hospital to Henan University of Science and Technology
Luoyang, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, China
Jiangsu Cancer Hospital
Nanjing, China
Nan Tong Tumor Hospital
Nantong, China
Shanghai Chest Hospital
Shanghai, China
Zhongshan Hospital Fudan University
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Cancer Hospital of Shantou University Medical College
Shantou, China
Liaoning Provincial Cancer Hospital
Shengyang, China
Suining Central Hospital
Suining, China
Tianjin Cancer Hospital
Tianjin, China
Weifang People's Hospital
Weifang, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Hubei Cancer Hospital
Wuhan, China
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital )
Wuxi, China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
Xi'an, China
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.